On 16 June 2020, Abcam plc announced that Jonathan Milner, co-founder and Non-Executive Deputy Chairman of Abcam, had informed the Board that he would be standing down from the Board in due course, to allow him to focus on his growing portfolio of early stage company investments.
Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces the following unaudited trading update ahead of reporting its results for the six months ended 31 December 2019 on 9 March 2020(1).
Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, is issuing today the following unaudited trading update for the year ended 30 June 2019 ahead of reporting its audited results on 9 September 2019.
Abcam plc (AIM: ABC) a global leader in the supply of life science research tools is pleased to announce its interim results for the six-month period ended 31 December 2018*.
Abcam (LSE: ABC), a global leader in the supply of life science research tools, is pleased to announce that it has acquired Calico Biolabs Inc., a developer of custom high-quality recombinant rabbit monoclonal antibodies for diagnostic and biopharmaceutical companies.
Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces the following unaudited trading update ahead of its results for the six months ended 31 December 2018.
Double-digit increase in revenue and earnings enables continued investment to sustain long-term growth. Abcam (AIM: ABC), a global leader in the supply of life science research tools, today announces its preliminary results for the year ended 30 June 2018.
Abcam plc (ABC), the online antibody sales company reported that sales increased 49.7% to £36.7m ($65.47m) in the year to June 30, while adjusted pretax profits increased 48.2% to £8.2m.